Flow cytometric analysis of bone marrow of tamoxifen-treated HSC-SCL-Cre-ERT;R26R-EYFP mice
. | . | Percent EYFP-positive cells within . | . | . | ||
|---|---|---|---|---|---|---|
| Tamoxifen regimen . | Day of analysis . | Total cells . | c-kit+Sca-1+lin- . | c-kit+Sca-1+lin-Flk-2- . | ||
| 5 mg day 1, 2 mg days 2-5, intraperitoneally | Day 6 | 1.0 ± 0.1 | 9.7 ± 4.4 | 36.5 ± 17.5 | ||
| Day 21 | 3.2 ± 0.6 | 16.0 ± 0.4 | 52.2 ± 8.2 | |||
| Feed (1 g/kg) days 1-21 | Day 21 | 14.8 ± 2.2 | 71.1 ± 8.4 | 98.5 ± 2.5 | ||
. | . | Percent EYFP-positive cells within . | . | . | ||
|---|---|---|---|---|---|---|
| Tamoxifen regimen . | Day of analysis . | Total cells . | c-kit+Sca-1+lin- . | c-kit+Sca-1+lin-Flk-2- . | ||
| 5 mg day 1, 2 mg days 2-5, intraperitoneally | Day 6 | 1.0 ± 0.1 | 9.7 ± 4.4 | 36.5 ± 17.5 | ||
| Day 21 | 3.2 ± 0.6 | 16.0 ± 0.4 | 52.2 ± 8.2 | |||
| Feed (1 g/kg) days 1-21 | Day 21 | 14.8 ± 2.2 | 71.1 ± 8.4 | 98.5 ± 2.5 | ||
Bone marrow cells were stained for hematopoietic progenitor populations and analyzed by flow cytometry. Data represent means ± SD of percentages obtained from at least 3 mice. Note a different schedule for tamoxifen administration and cell harvesting was used compared with Figure 2.